Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR2B | P41595 | 4/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403756 | 1.00 | PNMT (0.53) | PNMTHTR2CHTR2BTPSAB1ADRA2A | |
| Hydrochloric Acid SCHEMBL1242900 | 0.99 | PNMT (0.52) | PNMTHTR2CHTR2BTPSAB1ADRA2A | |
| Hydrochloric Acid SCHEMBL2405913 | 0.99 | PNMT (0.52) | PNMTHTR2CHTR2BTPSAB1ADRA2A | |
| SCHEMBL14947355 | 0.84 | TSHR (0.45) | HTR2CHTR2BPDE5ATSHRALDH1A1 | |
| SCHEMBL5628447 | 0.83 | PNMT (0.52) | PNMTHTR2CHTR2BTPSAB1ADRA2A | |
| SCHEMBL17258825 | 0.79 | PNMT (0.57) | PNMTHTR2CHTR2BTPSAB1ADRA2A | |
| SCHEMBL5630601 | 0.79 | HTR7 (0.45) | HTR2CHTR2BPDE5ATSHRALDH1A1 | |
| SCHEMBL2400927 | 0.78 | HRH3 (0.46) | TSHRALDH1A1 | |
| SCHEMBL1241268 | 0.78 | HRH3 (0.46) | TSHRALDH1A1 | |
| SCHEMBL2493535 | 0.78 | PDE5A (0.38) | HTR2CHTR2BPDE5ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1956962-B | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS | 2014-08-20 | — | — | CN | claimed |
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | claimed |
| US-8273733-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2012-09-25 | — | — | US | claimed |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | US | claimed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | claimed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | claimed |
| CN-1956962-A | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | CN | claimed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | claimed |
| EP-2556064-B1 | Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide | SANOFI SA (FR) | 2014-10-15 | — | — | EP | disclosed |
| CN-1956962-B | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS | 2014-08-20 | — | — | CN | disclosed |
| US-8748615-B2 | Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| CN-1956962-A | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | CN | disclosed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, SLC6A2, KCNQ2 | PNMT 30/4885HTR2C 23/4885HTR2B 25/4885 |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | PNMT 59/4885HTR2C 26/4885HTR2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.